Back to Search
Start Over
A study of 20 SLE patients with intravenous immunoglobulin clinical and serologic response
- Source :
- Lupus. 8:705-712
- Publication Year :
- 1999
- Publisher :
- SAGE Publications, 1999.
-
Abstract
- Objective: To test the clinical response of systemic lupus erythematosus (SLE) patients to intravenous immunoglobulins (IVIg), and whether the clinical response of IVIg treatment in SLE is accompanied by modification of SLE-associated autoantibodies/antibodies (Abs) and complement levels.Methods: Twenty SLE patients were treated with high-dose (2 g/kg) IVIg monthly, in a 5-d schedule. Each patient received between 1-8 treatment courses. They were evaluated for the clinical response, Systemic Lupus Activity Measure (SLAM) score before and after IVIg, levels of antinuclear antibody (ANA), dsDNA (double-stranded DNA), SS-A or SS-B, ENA (extractable nuclear antigens), C3and C4levels before and after the treatment, and before and after each treatment course.Results: A beneficial clinical response following IVIg treatment was noted in 17 out of 20 patients (85%). Few clinical manifestations responded more to treatment: arthritis, fever, thrombocytopenia, and neuropsychiatric lupus. In 9 patients evaluated before and after IVIg, mean SLAM score decreased from 19.3 ± 4.7 to 4 ± 2.9 (P < 0.0001). There was a tendency towards abnormal levels of complement and Abs before IVIg courses among the treatment responders compared with the non-responders, and similarly the former tended to have normalization of their abnormal levels more than the latter. These differences were found statistically significant only with respect to C4and SS-A or SS-B levels before IVIg courses.Conclusion: IVIg has a high response rate among SLE patients. A combination of clinical manifestations, Abs and complement levels may aid in the future in predicting who among SLE patients will benefit more from IVIg treatment.
- Subjects :
- Adult
Male
0301 basic medicine
Serology
03 medical and health sciences
0302 clinical medicine
Rheumatology
Antibody Specificity
Predictive Value of Tests
hemic and lymphatic diseases
Humans
Lupus Erythematosus, Systemic
Medicine
skin and connective tissue diseases
Autoantibodies
030203 arthritis & rheumatology
biology
business.industry
Autoantibody
Immunoglobulins, Intravenous
Middle Aged
Treatment Outcome
030104 developmental biology
Intravenous Immunoglobulins
Immunology
biology.protein
Female
Antibody
business
Anti-SSA/Ro autoantibodies
Subjects
Details
- ISSN :
- 14770962 and 09612033
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Lupus
- Accession number :
- edsair.doi.dedup.....34d6f0cb9c4ef63794b2296054954574